Navigation Links
AnaptysBio Expands Immunotherapy Portfolio With Anti-PD-1 Antibody Combinations

SAN DIEGO, Aug. 29, 2013 /PRNewswire/ -- AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced the expansion of its proprietary immunotherapy antibody portfolio to include multiple new combination therapies.  Using its SHM-XEL platform, the Company has recently developed a proprietary anti-PD-1 antibody, known as ANB011, with key differentiating advantages over competitors.  AnaptysBio is concurrently developing novel antibodies against other immune checkpoint receptors, including TIM-3 and LAG-3, which may be applied in combination with ANB011. 


Antibodies to immune checkpoint receptors have recently demonstrated promise in the treatment of various solid tumors, including metastatic melanoma, renal cell carcinoma and non-small cell lung cancer.  Although the normal function of immune checkpoint receptors is to maintain immune homeostasis, they are co-opted by certain tumors to evade immune surveillance.  By blocking the interaction of PD-1, TIM-3 and LAG-3 with their respective ligands, AnaptysBio's immunotherapy portfolio aims to restore immune function in cancer patients across a variety of tumor types.   These antibodies may also be combined with small molecule kinase inhibitors for additional anti-tumor activity.    

In addition to the immunotherapy portfolio described above, AnaptysBio has utilized its SHM-XEL platform to develop a novel antibody pipeline, including programs for pustular psoriasis, atopic dermatitis, muscle wasting disorders, fibrosis and antibody drug conjugate applications.

"We believe combination immunotherapy is an exciting paradigm in oncology and has the potential to provide durable anti-tumor effects for a broad range of patients," said Hamza Suria, president & chief executive officer of AnaptysBio. "Our SHM-XEL platform has permitted us to rapidly generate high potency antibodies against multiple immune checkpoint receptors." 

About AnaptysBio

AnaptysBio is a privately-held company focused on the generation of antibody therapeutics and is the leader in the use of somatic hypermutation (SHM) for antibody discovery and optimization. We are developing a pipeline of novel therapeutic antibody candidates, including differentiated programs in cancer immunotherapy, inflammation, fibrosis, muscle wasting disorders and antibody-drug conjugate applications.  AnaptysBio's proprietary SHM-XEL™ platform, which couples fully human antibody libraries with in vitro somatic hypermutation in mammalian cells to generate high affinity antibodies, replicates key features of the human immune system and overcomes limitations of prior antibody technologies.  By harnessing the natural mechanism of antibody maturation under controlled conditions, SHM-XEL allows for the selection of optimal antibody properties such as high affinity, stability, function, cross-reactivity, epitope diversity and manufacturability. The Company has previously announced partnerships with Merck, Roche, Novartis, Celgene, Gilead, DARPA and DTRA.  Major investors in AnaptysBio include Alloy Ventures, Avalon Ventures, Frazier Healthcare Ventures and Novo A/S.  For more information, visit

Julie Rathbun

SOURCE AnaptysBio, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Anaptysbio Expands Leadership Team With Addition Of Dr. Andrew J. Mcknight
2. AnaptysBio Develops Novel Antibody Scaffold With Extreme Thermostability
3. AnaptysBio Awarded U.S. Government Contract To Develop Anti-Ricin Antibodies
4. As Smartphone Usage Expands, Survey Says Nurses and Nursing Students Want Mobile Access to Credible Drug Data
5. BioSurplus Expands, Debuts New 8000 Square Foot Warehouse and Service Facility
6. RxAlly Expands National Network With Addition Of Nineteen Community Pharmacy Organizations Representing Over 2,000 Pharmacies
7. Clinical Interest in BioElectronics Products Expands to the Wound Care Market
8. S1 Biopharma Expands Focus to Include Male Sexual Health
9. PRA Expands Operations in Europe
10. USANA Health Sciences Expands Award-Winning Research and Development Team
11. Particle Sciences Expands its cGMP Capabilities with the Addition of Thin Films
Post Your Comments:
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ) today announced that ... York State Attorney General,s Office to end the ... statutes with the Attorney General over the decision of Forest ... selling the now generic version of memantine immediate release tablets.  ... released its counterclaims against New York , ...
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ), a ... start-up  biotechnology company focused on the development of ... by the F-Prime Biomedical Research Initiative (FBRI), today ... collaboration to support the discovery and development of ... Obsessive Compulsive disorders (OCD). ...
(Date:11/25/2015)... 2015 --> ... devices was valued at $11,171.1 million in 2014, and ... 5.7% during 2015 - 2022. The global market is ... of diabetes. In addition, the increase in obese population ... to the growth of the market. Furthermore, technological advancements ...
Breaking Medicine Technology:
(Date:11/26/2015)... CA (PRWEB) , ... November 26, 2015 , ... ... a new set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly ... options. These classically-influenced trailer titles work with any font, giving users limitless opportunities ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... the perfect dish and pleasing the palates of attendees is of the utmost ... dish to a seasonal get-together, give these recipes a try this holiday season. ...
(Date:11/25/2015)... ... November 26, 2015 , ... Ministers, senior government and ... Pan African Centres of Excellence, and public R&D institutions, civil societies and other ... of the 5th African Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dental professionals who would ... OH , are invited to attend Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE ... Cleveland, OH. , As the co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for the ... of the benefits of Botox® in the treatment of moderate facial wrinkling, few have ... pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism (the ...
Breaking Medicine News(10 mins):